Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High – Should You Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB)’s share price hit a new 52-week high on Wednesday . The stock traded as high as $35.66 and last traded at $35.3850, with a volume of 234834 shares. The stock had previously closed at $35.22.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GMAB shares. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Genmab A/S in a research note on Monday, September 14th. Guggenheim raised their target price on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Truist Financial assumed coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. Finally, New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.50.

Genmab A/S Stock Performance

The firm has a market capitalization of $21.89 billion, a PE ratio of 27.66, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $31.75 and a 200 day moving average price of $28.52.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Research analysts expect that Genmab A/S Sponsored ADR will post 1.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its stake in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after purchasing an additional 1,334,919 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Cibc World Market Inc. grew its position in shares of Genmab A/S by 31.2% in the 4th quarter. Cibc World Market Inc. now owns 367,282 shares of the company’s stock valued at $11,312,000 after buying an additional 87,350 shares during the last quarter. Finally, Quantinno Capital Management LP grew its position in shares of Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock valued at $7,579,000 after buying an additional 35,588 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.